COVID-19 Current Therapy Market Report 2026

The COVID-19 current therapy market size has declined steeply in recent years. It will decline from $2.35 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of -33.2%. The decline in the historic period can be attributed to sudden outbreak of COVID-19, high hospitalization rates, limited initial therapeutic options, decreasing government and healthcare initiatives, less emergency approvals for drugs.

The COVID-19 current therapy market size is expected to see steep decline in the next few years. It will decline to $0.31 billion in 2030 at a compound annual growth rate (CAGR) of -33.2%. The decline in the forecast period can be attributed to decreasing telemedicine adoption for COVID-19 management, less expansion of home care services. Major trends in the forecast period include rising adoption of antiviral and monoclonal antibody therapies, increased use of corticosteroids for severe COVID-19 cases, growth in home care and remote patient monitoring for COVID-19, expansion of supplement and immune support therapies, integration of combination and experimental therapies in treatment protocols.

The expansion of the healthcare infrastructure is expected to propel the growth of the COVID-19 current therapy market going forward. The healthcare industry refers to amalgamating and integrating the economic system’s sectors that offer products and services for curing, preventing, rehabilitating, and providing palliative care for patients. Healthcare infrastructure is pivotal for the effective implementation of COVID-19 therapies, ensuring timely patient care, supporting research and clinical trials, and providing essential resources for optimal treatment delivery. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the US increased to 6,129 from 6,093 in 2022. Furthermore, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK saw a significant of 9.4% in nominal terms and 9.7% in real terms. Therefore, the expansion of the healthcare industry is driving the growth of the COVID-19 current therapy market.

Major companies operating in the COVID-19 current therapy market are increasing their focus on introducing innovative products, such as COVID-19 oral antiviral treatment, to gain a competitive edge in the market. Antiviral treatment refers to the use of medications designed to inhibit the replication and spread of viruses within the body. For instance, in April 2024, Invivyd, a US-based company focuses on developing antibody-based therapies to address serious viral infectious diseases update on the launch of PEMGARDA™. Following its emergency use authorization (EUA) from The U.S. Food and Drug Administration (FDA). PEMGARDA quickly became available for commercial use. This treatment is aimed at preventing COVID-19 in individuals with moderate-to-severe immune compromise.

In July 2024, CureVac N.V., a Netherlands-based biotechnology company, partnered with GlaxoSmithKline plc (GSK), to restructure their mRNA vaccine collaboration into a new licensing agreement. With this partnership, CureVac N.V. and GlaxoSmithKline plc (GSK) aim to optimize the development and commercialization of mRNA-based vaccines by combining CureVac’s mRNA technology platform with GSK’s global regulatory, manufacturing, and commercial capabilities, enabling faster vaccine development, improved access, and expanded market reach worldwide. GlaxoSmithKline plc (GSK) is a UK-based pharmaceutical company that specializes in developing and commercializing vaccines, medicines, and consumer healthcare products.

Major companies operating in the COVID-19 current therapy market are Gilead Sciences Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals Inc., Canary Health Technologies, Thermo Fisher Scientific.

North America is the largest region in the COVID-19 current therapy market in 2025. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the COVID-19 current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the COVID-19 current therapy market by increasing the cost of imported antiviral drugs, monoclonal antibodies, corticosteroids, and digital monitoring devices. Hospital and clinic segments in North America, Europe, and parts of Asia relying heavily on imports are most affected. This has led to higher treatment costs and temporary supply chain disruptions. On the positive side, tariffs have encouraged local manufacturing, domestic production of therapies, and innovation in cost-effective treatment alternatives.

The COVID-19 current therapy market research report is one of a series of new reports that provides COVID-19 current therapy market statistics, including COVID-19 current therapy industry global market size, regional shares, competitors with a COVID-19 current therapy market share, detailed COVID-19 current therapy market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 current therapy industry. This COVID-19 current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

COVID-19 current therapy refers to the treatments and interventions employed to manage symptoms and reduce the severity of COVID-19. These therapies help alleviate respiratory distress, prevent complications, and support recovery in affected individuals. Key approaches include antiviral medications, corticosteroids, and supportive care.

The main types of drugs in COVID-19 current therapy include antivirals, monoclonal antibodies, corticosteroids, supplements, antimalarials, interferons and interleukin inhibitors, other anti-infective drugs, and more. Antivirals are medications designed to inhibit viral growth and replication by targeting specific stages of the viral life cycle or interfering with viral processes. They can be administered through various routes, including oral and intravenous. These therapies are used across hospitals, clinics, research institutes, and other healthcare settings.

The COVID-19 current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.